General Information |
| Summary |
The purpose of the study is to evaluate the safety of GRNOPC1 administered at a single time-point between 7 and 14 days post injury, inclusive, to patients with neurologically complete spinal cord injuries (SCI). |
| Description |
Not Provided |
| Clinical trials phase |
Phase 1 |
| Start date (estimated) |
2010-10-01 |
| End date (estimated) |
2013-07-31 |
| Clinical feature |
| Label |
Spinal Cord Injury |
| Link |
http://purl.obolibrary.org/obo/NCIT_C50750 |
| Description |
Traumatic damage of the spinal cord. |
|
Administrative Information |
| NCT number |
NCT01217008 |
| ICTRP weblink |
http://apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT01217008 |
| Other study identifiers |
|
| Source weblink |
https://clinicaltrials.gov/ct2/show/record/NCT01217008 |
| Regulatory body approval |
| Name |
Food and Drug Administration (FDA) |
| Country |
|
|
| Public contact |
| Email |
MedicalInquiries@asteriasbio.com |
| Country |
|
|
| Sponsors |
Asterias Biotherapeutics, Inc
|
Cell Line |
| Stem cell lines obtained from |
|
Recruitment |
| Recruitment Status |
Completed |
| Estimated number of participants |
5 |
